BioAge Labs (BIOA) reported a Q1 loss Friday of $0.52 per diluted share, wider than a loss of $0.36 a year earlier.

Analysts polled by FactSet expected a loss of $0.64.

Collaboration revenue for the quarter ended March 31 was $2.8 million, up from $1.5 million a year earlier.

Analysts surveyed by FactSet expected $1.1 million.

BioAge said that as of March 31 it had about $384.9 million in cash, cash equivalents, and marketable securities, which it expects to be enough to fund operations through 2029.